Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 25 Sep 2026
₹224.27
Change
+7.04 (3.24%)
Open
₹217.23
Prev. Close
₹217.23
Day High
₹227.0
Day Low
₹211.0
Volume Analysis
Traded
32,455
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (41.0%)
- •Strong 3-year revenue growth (18.8%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹246.52 | ₹236.76 | ₹230.52 | ₹220.76 | ₹214.52 | ₹204.76 | ₹198.52 |
| Fibonacci | ₹236.76 | ₹230.65 | ₹226.87 | ₹220.76 | ₹214.65 | ₹210.87 | ₹204.76 |
| Camarilla | ₹228.67 | ₹227.2 | ₹225.74 | ₹220.76 | ₹222.8 | ₹221.34 | ₹219.87 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-37.59%
1 Week
+11.57%
1 Month
+30.56%
3 Months
+15.17%
6 Months
+62.1%
1 Year
-34.2%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹124.64
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.24%
Net margin 12.24% × asset turnover 0.51x × equity multiplier 1.64x
Company Overview
Sector
Healthcare
Market Cap
₹786 Cr
P/E (TTM)
26.2
ROE
10.6%
Book Value
₹80.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Kilitch Drugs India Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Financial Strength (99/100), while Liquidity (1/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (41.0%).
TopFund Score — Fundamentals Quality
63/100 — AverageData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 54.7% CAGR over last 5 years
- +Company's median sales growth is 28.4% of last 10 years
- −Stock is trading at 2.81 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 10.2% over last 3 years.
- −Company has high debtors of 186 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
We are submitting herewith the publication of extract of the financial results for the quarter ended 30th June 2026
Monitoring agency report for ₹49.92 crore rights issue; no deviation, delayed ₹1.12 crore GCP utilized in Q1FY27.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 37 | 41 | 32 | 45 | 33 | 47 | 56 | 61 | 43 | 49 | 54 | 90 | 45 |
| Expenses + | 30 | 33 | 30 | 38 | 32 | 41 | 47 | 47 | 40 | 44 | 48 | 67 | 42 |
| Operating Profit | 6 | 9 | 2 | 7 | 2 | 6 | 9 | 15 | 3 | 5 | 6 | 22 | 3 |
| OPM % | 16.9% | 20.92% | 7.17% | 15.8% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.3% | 11.43% | 24.71% | 6.55% |
| Other Income + | 1 | 0 | 3 | 0 | 3 | 5 | 2 | 2 | 3 | 7 | 2 | 0 | 3 |
| Interest | 2 | 2 | 2 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 7 | 3 | 5 | 2 | 10 | 8 | 14 | 3 | 9 | 6 | 20 | 4 |
| Tax % | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.0% | 26.23% | 34.49% | 14.47% | 22.9% | 26.37% | 48.84% |
| Net Profit + | 3 | 5 | 2 | 4 | 0 | 9 | 6 | 10 | 2 | 8 | 4 | 15 | 2 |
| EPS in Rs | 1 | 1 | 1 | 1 | 0 | 2 | 2 | 3 | 1 | 2 | 1 | 4 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 | 237 |
| Expenses + | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 198 | 201 |
| Operating Profit | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 | 36 |
| OPM % | -9.0% | -19.0% | -2.0% | 11.0% | 9.0% | 0.8% | 8.0% | 9.0% | 13.0% | 16.0% | 16.0% | 16.0% | 15.0% |
| Other Income + | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 4 | 4 |
| Profit before tax | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 39 | 39 |
| Tax % | -70.0% | -4.0% | -5.0% | 16.0% | 55.0% | 48.0% | 27.0% | 35.0% | 31.0% | 30.0% | 28.0% | 24.0% | — |
| Net Profit + | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 | 29 |
| EPS in Rs | 0 | -4 | -3 | 2 | 1 | 0 | 1 | 2 | 3 | 4 | 8 | 9 | 9 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 13.0% | 20.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings + | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other Liabilities + | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets + | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other Assets + | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Cash from Investing Activity + | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Cash from Financing Activity + | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| Net Cash Flow | -39 | -2 | 0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 | 6 |
| CFO/OP | 430 | -442 | -202 | 25 | 60 | 1,598 | 877 | 79 | 39 | 23 | 82 | 92 |
| Free Cash Flow | -10 | -26 | 0 | -2 | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.78% | 30.76% | 30.77% | 30.77% | 30.77% | 30.76% | 30.77% | 30.77% | 36.22% | 36.23% | 36.22% | 36.11% |
| Promoters | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 69.23% | 63.77% | 63.77% | 63.77% | 63.77% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.12% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Kilitch Drugs India Ltd (this stock) | 786 | 26.2 | 2.81 | 10.6% |
| Wanbury Limited | 784 | 18.2 | 12.38 | 76.5% |
| Gaudium Ivf N Women H L | 837 | 36.2 | 5.55 | 24.7% |
| Bafna Pharmaceuticals Ltd | 842 | — | 1.65 | -6.18% |
| Zim Laboratories Limited | 716 | 194.0 | 2.42 | 1.59% |
| Valiant Laboratories Ltd | 678 | 42.4 | 2.19 | -1.2% |
| Health X Platform Limited | 908 | 510.0 | 1.42 | 0.29% |
Which Mutual Funds Hold Kilitch Drugs India Ltd?
Frequently Asked Questions about Kilitch Drugs India Ltd
Kilitch Drugs India Ltd (KILITCH) closed at ₹224.27 on NSE on 25 September 2026, up 7.04 (3.24%) from the previous close.
Kilitch Drugs India Ltd trades on the NSE (National Stock Exchange of India) under the symbol KILITCH.
Kilitch Drugs India Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 26.2.
Kilitch Drugs India Ltd has a dividend yield of 0.0%.
Kilitch Drugs India Ltd's 52-week high is ₹234.0 and its 52-week low is ₹117.0.
Kilitch Drugs India Ltd has a market capitalisation of ₹786 crore.
Kilitch Drugs India Ltd has a TopFund Quality Score of 63/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Kilitch Drugs India Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.